Dialog Box

Help OCA advocate for the listing of Niraparib on the PBS

OCA TO MAKE SUBMISSION TO PBAC REGARDING NIRAPARIB

HAVE YOUR SAY


Niraparib is a PARP inhibitor drug, that has been approved by the Therapeutic Goods Administration (TGA) for women who have experienced recurrent ovarian cancer and are in response to platinum based chemotherapy, regardless of whether or not they have an identified BRCA mutation.

The next step in the process is for the drug to be listed on the Pharmaceutical Benefits Scheme (PBS). The PBS is the main mechanism via which the Government subsidises the cost of medications used by the community. Medicines can only be included on the PBS if recommended for listing by the Pharmaceutical Benefits Advisory Committee (PBAC), an independent expert body that includes health professionals, consumer nominees and an industry nominee.

OCA is making a submission to the Pharmaceutical Benefits Advisory Committee (PBAC) regarding Niraparib, and we are encouraging consumers to become involved and have your say in one of two ways:

  • Firstly, you are able to make a direct submission via the consumer comments form on the PBAC website by 5pm on Wednesday 10th February 2021 PBS website
  • Alternatively, you are able to complete our OCA survey on the issue, and we will include your responses in our OCA submission. Please note this survey will close on 3rd February 2021 to allow us time to collate the responses 

Take the survey now 

We understand this process can be confusing, so we have put together some Frequently Asked Questions that may be useful.

For any enquiries about the submission, or other information or support, please speak with one of our ovarian cancer nurses via Helpline on 1300 660 334 (9 am – 5pm AEDT).


FREQUENTLY ASKED QUESTIONS

What is Niraparib and how is it different to Olaparib?

Niraparib is a type of targeted therapy called a PARP inhibitor. The only PARP inhibitor currently approved for use in Australia is Olaparib, which is only available to those with a BRCA mutation. Niraparib has shown benefit in those with and without a BRCA mutation, so approval of Niraparib would allow a greater number of women with ovarian cancer to access PARP inhibitor medications.


What is the Pharmaceutical Benefits Scheme (PBS)?

The PBS is the main mechanism through which the Government subsidises the cost of medications used by the community.

Medicines can only be included on the PBS if recommended for listing by the Pharmaceutical Benefits Advisory Committee (PBAC).


What is the Pharmaceutical Benefits Advisory Committee (PBAC)?

PBAC is an independent expert body that includes health professionals, consumer nominees and an industry nominee.


How and when will we know if the application is successful?

The outcomes of each PBAC meeting are available on the PBS website 6 weeks after each meeting (this meeting is scheduled for March 2021.) OCA will communicate the outcome with our community.


How can I know if I am eligible and access medications like this or other new treatment options?

Whilst OCA endeavours to update our community on new treatments available, we recommend women discuss eligibility for drugs with their treatment team, who are best able to advise on treatment options including compassionate access schemes and clinical trials.



13 January 2021
Category: News
Tags:
Donate